BUY NOW For Sale 70%!
buy viagra

Prezzo zithromax compresse

  • 1.

    McGuire JM, Bunch R, Anderson RC, Boaz HE, Flynn EH, Powell HM, et al.(1952) ‘Ilotycin’ an new antibiotic. Antibiot Chemother 2:281–283Google Scholar

  • 2.

    Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A (1991) Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 58:145–149PubMedCrossRefGoogle Scholar

  • 3.

    Kudoh S, Kimura H, Uetake T, et al.(1984) Clinical effect of low-dose, long-term macrolide antibiotic chemotherapy on diffuse panbronchiolitis. Jpn J Thorac Dis 22:254Google Scholar

  • 4.

    Kikuchi S, Susaki H, Aoki A, Ito O, Nomura Y (1991) Clinical effect of long-term low-dose erythromycin therapy for chronic sinusitis (in Japanese with English abstract). Pract Otlo (Koyoto) 84:41–47Google Scholar

  • 5.

    Stein GE, Havlichek DH (1992) The new macrolide antibiotics. Azithromycin and clarithromycin. Postgrad Med 92:269–272, 77–82Google Scholar

  • 6.

    Hirakata Y, Kaku M, Mizukane R, Ishida K, Furuya N, Matsumoto T, et al.(1992) Potential effects of erythromycin on host defense systems and virulence of Pseudomonas aeruginosa. Antimicrob Agents Chemother 36:1922–1927PubMedGoogle Scholar

  • 7.

    Sofer D, Gilboa-Garber N, Belz A, Garber NC (1999) ‘Subinhibitory’ erythromycin represses production of Pseudomonas aeruginosa lectins, autoinducer and virulence factors. Chemotherapy 45:335–341PubMedCrossRefGoogle Scholar

  • 8.

    Wozniak DJ, Keyser R (2004) Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 125(2 Suppl):62S–69S; quiz 9SPubMedCrossRefGoogle Scholar

  • 9.

    Takeoka K, Ichimiya T, Yamasaki T, Nasu M (1998) The in vitro effect of macrolides on the interaction of human polymorphonuclear leukocytes with Pseudomonas aeruginosa in biofilm. Chemotherapy 44:190–197PubMedCrossRefGoogle Scholar

  • 10.

    Nalca Y, Jansch L, Bredenbruch F, Geffers R, Buer J, Haussler S (2006) Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. Antimicrob Agents Chemother 50:1680–1688PubMedCrossRefGoogle Scholar

  • 11.

    Stein G, Havlicheck DH (1992) The new macrolide antibiotics: azithromycin and clarithromycin. Postgrad Med 92:269–282PubMedGoogle Scholar

  • 12.

    Bermudez L, Inderlied C, Young LS (1991) Stimulation with cytokines enhances penetration of azithromycin into human macrophages. Antimicrob Agents Chemother 35:2625–2629PubMedGoogle Scholar

  • 13.

    Lennard CM, Mann EA, Sun LL, Chang AS, Bolger WE (2000) Interleukin-1 beta, interleukin-5, interleukin-6, interleukin-8, and tumor necrosis factor-alpha in chronic sinusitis: response to systemic corticosteroids. Am J Rhinol 14:367–373PubMedCrossRefGoogle Scholar

  • 14.

    Wallwork B, Coman W, Feron F, Mackay-Sim A, Cervin A (2002) Clarithromycin and prednisolone inhibit cytokine production in chronic rhinosinusitis. Laryngoscope 112:1827–1830PubMedCrossRefGoogle Scholar

  • 15.

    Suzuki H, Asada Y, Ikeda K, Furukawa M, Oshima T, Takasaka T (1999) Inhibitory effect of erythromycin on interleukin-8 secretion from exudative cells in the nasal discharge of patients with chronic sinusitis. Laryngoscope 109:407–410PubMedCrossRefGoogle Scholar

  • 16.

    Wallwork B, Coman W, Mackay-Sim A, Cervin A (2004) Effect of clarithromycin on nuclear factor-kappa B and transforming growth factor-beta in chronic rhinosinusitis. Laryngoscope 114:286–290PubMedCrossRefGoogle Scholar

  • 17.

    Inamura K, Ohta N, Fukase S, Kasajima N, Aoyagi M (2000) The effect of erythromycin on human peripheral neutrophil apoptosis. Rhinology 38:124–129PubMedGoogle Scholar

  • 18.

    Aoshiba K, Nagai A, Konno K (1995) Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrob Agents Chemother 39:872–877PubMedGoogle Scholar

  • 19.

    Hand W, Hand D, King-Thompson N (1990) Antibiotic inhibition of the respiratory burst response in human polymorphonuclear leukocytes. Antimicrob Agents Chemother 34:863–870PubMedGoogle Scholar

  • 20.

    Braga P, Maci S, Dal Sasso M, Fonti E, Ghessi A (1997) Effects of rokitamycin on phagocytosis and release of oxidant radicals of human polymorphonuclear leukocytes. Chemotherapy 43:190–197PubMedCrossRefGoogle Scholar

  • 21.

    Lin H, Wang C, Liu C, Yu C, Kuo H (2000) Erythromycin inhibits beta2-integrins (CD11b/CD18) expression, interleukin-8 release and intracellular oxidative metabolism in neutrophils. Respir Med 94:654–660PubMedCrossRefGoogle Scholar

  • 22.

    Matsuoka N, Eguchi K, Kawakami A, Tsuboi M, Kawabe Y, Aoyagi T, Nagataki S (1996) Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells. Clin Exp Immunol 104:501–508PubMedCrossRefGoogle Scholar

  • 23.

    Baeuerle P, Henkel T (1994) Function and activation of NF-kappaB in the immune system. Annu Rev Immunol 12:141–179PubMedGoogle Scholar

  • 24.

    Miyanohara T, Ushikai M, Matsune S, Ueno K, Katahira S, Kurono Y (2000) Effects of clarithromycin on cultured human nasal epithelial cells and fibroblasts. Laryngoscope 110:126–131PubMedCrossRefGoogle Scholar

  • 25.

    Desaki M, Takizawa H, Ohtoshi T, Kasama T, Kobayashi K, Sunazuka T, Omura S, Yamamoto K, Ito K (2000) Erythromycin suppresses nuclear factor kappa-B and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun 267:124–128PubMedCrossRefGoogle Scholar

  • 26.

    Nakano T, Ohashi Y, Tanaka A, Kakinoki Y, Washio Y, Nakai Y (1998) Roxithromycin reinforces epithelial defence function in rabbit trachea. Acta Otolaryngol Suppl 538:233–238PubMedCrossRefGoogle Scholar

  • 27.

    Tamaoki J, Takeyama K, Yamawaki I, Kondo M, Konno K (1997) Lipopolysaccharide-induced goblet cell hypersecretion in the guinea pig trachea: inhibition by macrolides. Am J Physiol 272:15–19Google Scholar

  • 28.

    Rhee C, Majima Y, Arima S, Jung H, Jinn T, Min Y, Sakakura Y (2000) Effects of clarithromycin on rheological properties of nasal mucous in patients with chronic sinusitis. Ann Otol Rhinol Laryngol 109:484–487PubMedGoogle Scholar

  • 29.

    Rubin B, Druce H, Ramirez OE, Palmer R (1997) Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 155:2018–2023PubMedGoogle Scholar

  • 30.

    Nishi K, Mizuguchi M, Tachibana H, et al.(1995) Effect of clarithromycin on symptoms and mucociliary transport in patients with sino-bronchial syndrome. Nippon Shikkan Gakkai Zasshi 33:1392–1400Google Scholar

  • 31.

    Wallwork B, Coman W, Mackay-Sim A, Greiff L, Cervin A (2006) A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis. Laryngoscope 116:189–193PubMedCrossRefGoogle Scholar

  • 32.

    Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M (1998) Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 157:1829–1832PubMedGoogle Scholar

  • 33.

    Pukhalsky AL, Shmarina GV, Kapranov NI, Kokarovtseva SN, Pukhalskaya D, Kashirskaja NJ (2004) Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediators Inflamm 13:111–117PubMedCrossRefGoogle Scholar

  • 34.

    Equi A, Balfour-Lynn IM, Bush A, Rosenthal M (2002) Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 360:978–984PubMedCrossRefGoogle Scholar

  • 35.

    Equi AC, Davies JC, Painter H, Hyde S, Bush A, Geddes DM, et al.(2006) Exploring the mechanisms of macrolides in cystic fibrosis. Respir Med 100:687–697PubMedCrossRefGoogle Scholar

  • 36.

    Saiman L, Mayer-Hamblett N, Campbell P, Marshall BC (2005) Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 172:1008–1012PubMedCrossRefGoogle Scholar

  • 37.

    Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al.(2003) Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290:1749–1756PubMedCrossRefGoogle Scholar

  • 38.

    Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J (2002) Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 57:212–216PubMedCrossRefGoogle Scholar

  • 39.

    Black PN, Blasi F, Jenkins CR, Scicchitano R, Mills GD, Rubinfeld AR, et al.(2001) Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med 164:536–541PubMedGoogle Scholar

  • 40.

    Kostadima E, Tsiodras S, Alexopoulos EI, Kaditis AG, Mavrou I, Georgatou N, et al.(2004) Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur Respir J 23:714–717PubMedCrossRefGoogle Scholar

  • 41.

    Kraft M, Cassell GH, Pak J, Martin RJ (2002) Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest 121:1782–1788PubMedCrossRefGoogle Scholar

  • 42.

    Shoji T, Yoshida S, Sakamoto H, Hasegawa H, Nakagawa H, Amayasu H (1999) Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clin Exp Allergy 29:950–956PubMedCrossRefGoogle Scholar

  • 43.

    Banerjee D, Khair OA, Honeybourne D (2005) The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respir Med 99:208–215PubMedCrossRefGoogle Scholar

  • 44.

    Banerjee D, Honeybourne D, Khair OA (2004) The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial. Treat Respir Med 3:59–65PubMedCrossRefGoogle Scholar

  • 45.

    Koh YY, Lee MH, Sun YH, Sung KW, Chae JH (1997) Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J 10:994–999PubMedCrossRefGoogle Scholar

  • 46.

    Nakamura H, Fujishima S, Inoue T, Ohkubo Y, Soejima K, Waki Y, et al.(1999) Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J 13:1371–1379PubMedCrossRefGoogle Scholar

  • 47.

    MacLeod CM, Hamid QA, Cameron L, Tremblay C, Brisco W (2001) Anti-inflammatory activity of clarithromycin in adults with chronically inflamed sinus mucosa. Adv Ther 18:75–82PubMedCrossRefGoogle Scholar

  • 48.

    Suzuki H, Shimomura A, Ikeda K, Oshima T, Takasaka T (1997) Effects of long-term low-dose macrolide administration on neutrophil recruitment and IL-8 in the nasal discharge of chronic sinusitis patients. Tohoku J Exp Med 182:115–124PubMedCrossRefGoogle Scholar

  • 49.

    Yamada T, Fujieda S, Mori S, Yamamoto H, Saito H (2000) Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. Am J Rhinol 14:143–148PubMedCrossRefGoogle Scholar

  • 50.

    Rhee CS, Majima Y, Arima S, Jung HW, Jinn TH, Min YG, et al.(2000) Effects of clarithromycin on rheological properties of nasal mucus in patients with chronic sinusitis. Ann Otol Rhinol Laryngol 109:484–487PubMedGoogle Scholar

  • 51.

    Ichimura K, Shimazaki Y, Ishibashi T, Higo R (1996) Effect of new macrolide roxithromycin upon nasal polyps associated with chronic sinusitis. Auris Nasus Larynx 23:48–56PubMedGoogle Scholar

  • 52.

    Hashiba M, Baba S (1996) Efficacy of long-term administration of clarithromycin in the treatment of intractable chronic sinusitis. Acta Otolaryngol Suppl (Stockh) 525:73–78Google Scholar

  • 53.

    Cervin A, Kalm O, Sandkull P, Lindberg S (2002) One-year low-dose erythromycin treatment of persistent chronic sinusitis after sinus surgery: clinical outcome and effects on mucociliary parameters and nasal nitric oxide. Otolaryngol Head Neck Surg 126:481–489PubMedCrossRefGoogle Scholar

  • 54.

    Ragab SM, Lund VJ, Scadding G (2004) Evaluation of the medical and surgical treatment of chronic rhinosinusitis: a prospective, randomised, controlled trial. Laryngoscope 114:923–930PubMedCrossRefGoogle Scholar

  • 55.

    Moriyama H, Yanagi K, Ohtori N, Fukami M (1995) Evaluation of endoscopic sinus surgery for chronic sinusitis: post-operative erythromycin therapy. Rhinology 33:166–170PubMedGoogle Scholar

  • 56.

    Suzuki H, Ikeda K, Honma R, Gotoh S, Oshima T, Furukawa M, et al.(2000) Prognostic factors of chronic rhinosinusitis under long-term low-dose macrolide therapy. ORL J Otorhinolaryngol Relat Spec 62:121–127PubMedGoogle Scholar

  • 57.

    Kimura N, Nishioka K, Nishizaki K, Ogawa T, Naitou Y, Masuda Y (1997) Clinical effect of low-dose, long-term roxithromycin chemotherapy in patients with chronic sinusitis. Acta Med Okayama 51:33–37PubMedGoogle Scholar

  • 58.

    Iino Y, Sugita K, Toriyama M, Kudo K (1993) Erythromycin therapy for otitis media with effusion in sinobronchial syndrome. Arch Otolaryngol Head Neck Surg 119:648–651PubMedGoogle Scholar


Source: https://link.springer.com/chapter/10.1007/978-3-540-74380-4_25


BUY NOW For Sale 70%!
buy viagra

1000 Mg Dose Of Azithromycin Zithromax dosage wikipedia

Prezzo zithromax compresse Velamox 250mg 5ml - Tratamento de Infeces - Sare Drogarias
Prezzo zithromax compresse Zithromax (Azithromycin Side Effects, Interactions, Warning, Dosage)
Prezzo zithromax compresse Azithromycin and Alcohol Safety Considerations - Healthline
Prezzo zithromax compresse Pariuri sportive, pariuri live, casino, loto, virtuale - Superbet
Prezzo zithromax compresse How much caffeine in bigelow green tea with mint dexamethasone
Prezzo zithromax compresse Zithromax 500mg Pills
BUY NOW For Sale 70%!
buy viagra